Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Generation, validation and use of a synthetic reporter of CAR T cell products function and dysfunction

Project description

Synthetic reporter to detect T cell dysfunction in cancers

Cell-based immunotherapy, particularly adoptive cell transfer (ACT) with engineered T cells, holds promise for treating cancer. However, challenges such as manufacturing processes, excessive antigen exposure, and a hostile tumour microenvironment can lead to dysfunctional T cell products, reducing their effectiveness against both blood cancers and solid tumours. The ERC-funded SynT project aims to develop a synthetic reporter system to detect T cell dysfunction, utilising dual synthetic locus control region (sLCR) reporters. One reporter will indicate when T cells are in ‘serial killer’ mode, while the other will signal dysfunction. The project will also identify external signalling and pharmacological modulators to enhance CAR T cell function and develop a media supplement to improve the effectiveness of ACT products.

Objective

"Cell-based immunotherapy, particularly adoptive cell transfer (ACT) using engineered T cells, holds great promise as a therapeutic strategy for cancer treatment. However, challenges such as the manufacturing process, excessive antigen exposure, and the hostile tumor microenvironment often lead to dysfunctional T cell products, limiting their effectiveness in treating both blood cancers and solid tumors. We propose a novel tool to define in vitro conditions to enhance T cell product fitness through the development of a synthetic reporter system for detecting T cell dysfunction states, referred to as SynT. This innovative system will incorporate a dual synthetic locus control region (sLCR) reporter, with one sLCR reporter indicating T cells in a potent ""serial killer"" mode and another sLCR reporter representing T cell dysfunction. By using SynT, we aim to screen for external signaling and pharmacological modulators that can enrich and reverse the dysfunctional state in CAR T cells. we will generate and validate a synthetic reporter of CAR T cell products function and dysfunction, and produce a media supplement that promotes ACT products functions.
"

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2023-POC

See all projects funded under this call

Host institution

MAX DELBRUECK CENTRUM FUER MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT (MDC)
Net EU contribution
€ 150 000,00
Address
ROBERT ROSSLE STRASSE 10
13125 Berlin
Germany
Region
Berlin Berlin Berlin
Activity type
Research Organisations
Links
Total cost
No data

Beneficiaries (1)